Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA).
ALD and SARS-CoV-2
Alcohol use disorder
Alcohol-related liver cirrhosis
Alcohol-related liver disease
Management of AUD
SARS-CoV-2 infection
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
20
07
2020
accepted:
14
04
2021
pubmed:
19
6
2021
medline:
9
6
2022
entrez:
18
6
2021
Statut:
ppublish
Résumé
Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19. The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19. A panel of experts of the Italian Society of Alcohology (SIA) met via "conference calls" during the lockdown period to draft the SIA's criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era. The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.
Sections du résumé
BACKGROUND
Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19.
AIMS
The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19.
METHODS
A panel of experts of the Italian Society of Alcohology (SIA) met via "conference calls" during the lockdown period to draft the SIA's criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era.
RESULTS AND CONCLUSIONS
The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.
Identifiants
pubmed: 34142284
doi: 10.1007/s10620-021-07006-1
pii: 10.1007/s10620-021-07006-1
pmc: PMC8210966
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1975-1986Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Dig Liver Dis. 2020 Mar;52(3):358-359
pubmed: 31874833
Cochrane Database Syst Rev. 2017 Sep 25;9:CD011479
pubmed: 28944453
Biochem Biophys Res Commun. 2020 May 21;526(1):135-140
pubmed: 32199615
Arthritis Rheumatol. 2017 Sep;69(9):1751-1761
pubmed: 28597609
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Addiction. 2011 Apr;106(4):729-36
pubmed: 21134019
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
J Clin Gastroenterol. 2021 Jan;55(1):1-11
pubmed: 33230011
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
J Clin Pharmacol. 2002 Oct;42(10):1122-33
pubmed: 12362927
J Telemed Telecare. 2018 Jan;24(1):4-12
pubmed: 29320966
Lancet. 2019 Aug 31;394(10200):781-792
pubmed: 31478502
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Clin Liver Dis. 2019 Feb;23(1):11-23
pubmed: 30454825
SN Compr Clin Med. 2020;2(12):2637-2646
pubmed: 33163859
Drug Alcohol Depend. 2013 Nov 1;133(1):15-29
pubmed: 23746430
Dig Liver Dis. 2019 Oct;51(10):1423-1429
pubmed: 31113738
Hepatology. 2018 Oct;68(4):1621-1632
pubmed: 29689120
J Hepatol. 2021 Jan;74(1):148-155
pubmed: 32750442
Clin Toxicol (Phila). 2006;44(2):173-5
pubmed: 16615675
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041
pubmed: 32936252
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
FASEB J. 2020 May;34(5):6027-6037
pubmed: 32350928
Clin Transl Sci. 2020 Sep;13(5):880-885
pubmed: 32475019
Metab Brain Dis. 2012 Dec;27(4):567-72
pubmed: 22791269
Br J Hosp Med (Lond). 2018 Feb 2;79(2):93-96
pubmed: 29431486
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Asian J Psychiatr. 2020 Jun;51:102092
pubmed: 32315963
Am J Psychiatry. 2014 Apr;171(4):404-15
pubmed: 24362450
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7
pubmed: 14986280
Hepatology. 2020 Jul;72(1):287-304
pubmed: 32298473
J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324
pubmed: 32238757
Dig Dis Sci. 2020 Jul;65(7):1932-1939
pubmed: 32447742
Expert Opin Drug Saf. 2020 Feb;19(2):159-166
pubmed: 31876433
Lancet Gastroenterol Hepatol. 2020 May;5(5):485-493
pubmed: 32277901
Clin Pharmacol Ther. 2020 Oct;108(4):791-797
pubmed: 32324898
Expert Opin Ther Pat. 2021 Apr;31(4):295-307
pubmed: 33283567
Lancet Public Health. 2020 May;5(5):e259
pubmed: 32277874
J Hepatol. 2020 Nov;73(5):1231-1240
pubmed: 32553666
J Hepatol. 2018 Jul;69(1):154-181
pubmed: 29628280
J Dig Dis. 2020 Mar;21(3):125-126
pubmed: 32096611
Pharmacopsychiatry. 2016 Jul;49(4):137-41
pubmed: 26987743
Psychosomatics. 2018 Mar - Apr;59(2):105-122
pubmed: 29275963
Drug Saf. 2008;31(10):851-65
pubmed: 18759509
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Immunopharmacology. 2000 May;47(2-3):85-118
pubmed: 10878285
Eur Neuropsychopharmacol. 2014 Feb;24(2):181-91
pubmed: 24182622
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
J Hepatol. 2018 Sep;69(3):718-735
pubmed: 29777749
Gastroenterology. 2020 May;158(6):1518-1519
pubmed: 32142785
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
Pharmacotherapy. 2020 May;40(5):416-437
pubmed: 32259313
Arthritis Rheum. 1990 Nov;33(11):1611-9
pubmed: 2242059
Lancet Gastroenterol Hepatol. 2020 May;5(5):507-514
pubmed: 32277903
Eur J Pharmacol. 2013 Oct 15;718(1-3):323-31
pubmed: 24012782
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Alcohol Clin Exp Res. 2008 Jul;32(7):1105-10
pubmed: 18540918
Lancet. 2016 Mar 5;387(10022):988-998
pubmed: 26343838
Hepatology. 2020 Aug;72(2):723-728
pubmed: 32275784
Pharmacol Res. 2018 Jul;133:65-76
pubmed: 29719204
Hepatol Int. 2017 May;11(3):255-267
pubmed: 28247264
J Med Internet Res. 2020 Jan 31;22(1):e13252
pubmed: 32012048
Expert Opin Drug Saf. 2018 Feb;17(2):169-177
pubmed: 29120249
Am J Transplant. 2020 Jul;20(7):1939-1940
pubmed: 32181969
Int J Telemed Appl. 2018 Mar 11;2018:3932643
pubmed: 29713341
Minerva Med. 2020 Feb;111(1):1-3
pubmed: 31359740
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-787
pubmed: 32585136
JHEP Rep. 2020 Oct;2(5):100169
pubmed: 32835190
Lancet Psychiatry. 2019 Dec;6(12):1068-1080
pubmed: 31630984
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2003 Dec 18;349(25):2431-41
pubmed: 14681510
Alcohol. 1986 Nov-Dec;3(6):357-9
pubmed: 3028446
Nat Rev Dis Primers. 2018 Aug 16;4(1):16
pubmed: 30115921
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Am J Transplant. 2020 Jul;20(7):1840-1848
pubmed: 32330351
Dig Liver Dis. 2020 Jan;52(1):21-32
pubmed: 31757596
Drugs. 2015 Jul;75(11):1255-68
pubmed: 26084940
Aliment Pharmacol Ther. 2020 Jul;52(2):267-275
pubmed: 32402090
Arch Gen Psychiatry. 2010 Oct;67(10):1069-77
pubmed: 20921123
Hepatol Int. 2020 Sep;14(5):621-637
pubmed: 32710250
Minerva Gastroenterol Dietol. 2020 Jun;66(2):90-92
pubmed: 32221278
JAMA Psychiatry. 2015 Aug;72(8):757-66
pubmed: 26039070
Hepatology. 2020 Sep;72(3):1102-1108
pubmed: 32369624